Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 5
Submit an article Journal homepage
359
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement

Anath C. Lionela Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Ashwath Gurumurthia Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Ahmed Fetooha Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Rami Eldayab Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Sairah Ahmeda Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Swaminathan P. Iyera Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Loretta J. Nastoupila Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Jason Westina Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Ranjit Naira Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Luis Fayada Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Luis Malpicaa Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Sudhakar Tummalac Department of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Christopher Flowersa Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Sattva S. Neelapua Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Michael L. Wanga Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Preetesh Jaina Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2735-168XView further author information
ORCID Icon show all
Pages 669-673 | Received 27 Nov 2023, Accepted 08 Jan 2024, Published online: 22 Jan 2024

References

  • Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. doi:10.1056/NEJMoa1914347
  • Cheah CY, George A, Giné E, et al. Central nervous system involvement in mantle cell lymphoma: clinical ­features, prognostic factors and outcomes from the european mantle cell lymphoma network. Ann Oncol. 2013;24(8):2119–2123. doi:10.1093/annonc/mdt139
  • Rusconi C, Cheah CY, Eyre TA, et al. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with Central nervous system relapse. Blood. 2022;140(17):1907–1916. doi:10.1182/blood.2022015560
  • Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41(14):2594–2606. doi:10.1200/JCO.22.01797
  • Vu K, Frank MJ. CAR T-cell therapy for mantle cell lymphoma with Central nervous system relapse. Blood Adv. 2023;7(3):375–378. doi:10.1182/bloodadvances.2022008031
  • Caillet A, Houillier C, Sourdeau E, et al. Successful treatment by CAR T-cells in multi-refractory mantle cell lymphoma with Central nervous system involvement. Ann Hematol. 2023;102(11):3295–3297. doi:10.1007/s00277-023-05408-x
  • Ryan CE, Zon RL, Redd R, et al. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary Central nervous system involvement. Br J Haematol. 2023;203(5):774–780. doi:10.1111/bjh.19037
  • Khurana A, Dalland JC, Young JR, et al. Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis. Am J Hematol. 2021;96(8):E298–E301.
  • Munoz JL, Wang Y, Jain P, et al. BTK inhibitors and CAR T-cell therapy in treating mantle cell lymphoma-Finding a dancing partner. Curr Oncol Rep. 2022;24(10):1299–1311. doi:10.1007/s11912-022-01286-0
  • Minson AG, Hamad N, Cheah CY, et al. CAR T-cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: phase II TARMAC study. Blood. 2023.
  • Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. doi:10.1016/j.bbmt.2018.12.758
  • McLaughlin N, Wang Y, Witzig T, et al. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023;64(2):371–377. doi:10.1080/10428194.2022.2148211
  • Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650–1660. doi:10.1182/blood.2019002936
  • Liu M, Deng H, Mu J, et al. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Cancer Sci. 2021;112(7):2642–2651. doi:10.1111/cas.14915
  • Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–1127. doi:10.1182/blood-2015-11-679134
  • Qin JS, johnstone TG, baturevych A, hause RJ, ragan SP, clouser CR, et al. Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib. J immunother. 2020;43(4):107–20. doi:10.1097/CJI.0000000000000307[PMC].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.